8-K: Arcturus CFO Sassine Departs, Roberts Named Interim

Arcturus Therapeutics announced the mutual separation of CFO Andy Sassine and the appointment of Controller Joe Roberts as interim principal financial and accounting officer.

Summary

• Andy Sassine, Chief Financial Officer and Board member, mutually agreed to end his employment with Arcturus Therapeutics Holdings Inc. effective December 31, 2025.
• Mr. Sassine also stepped down from the Board of Directors on December 11, 2025, and his separation was not due to any disagreement with the Company, Board, or management.
• The Board decreased its size from nine to eight members immediately following Mr. Sassine's resignation.
• Mr. Sassine will receive a lump sum severance payment equal to 12 months of his base salary, amounting to $572,000.
• He is eligible for a bonus for 2025, calculated as the same percentage of his 50% target bonus as the CEO receives of their 60% target bonus, payable by March 15, 2026.
• The Company will reimburse up to $10,000 for his reasonable attorneys' fees related to the Separation Agreement.
• Arcturus will pay COBRA healthcare premiums for Mr. Sassine and his eligible dependents for up to 18 months.
• All unvested stock options held by Mr. Sassine (134,689 shares as of November 25, 2025) will accelerate and become immediately exercisable upon the Separation Date.
• Mr. Sassine has a 24-month period, beginning December 31, 2025, to exercise all his stock options, totaling 676,250 shares.
• Joe Roberts, age 43, the Company's Controller, was appointed interim principal financial officer and interim principal accounting officer on December 12, 2025.
• Mr. Roberts joined Arcturus in July 2018 and has held roles of increasing seniority, becoming Controller in March 2024.
• His current base salary is $219,580, with bonus eligibility up to 20% of base salary, and he participates in the Company's 401K, equity incentive, health care, and other plans.
• No changes to Mr. Roberts' compensation were made in connection with his interim appointment.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the departure of a CFO can be seen as a negative, the amicable nature of the separation and the immediate appointment of an internal interim replacement mitigate significant negative impact. The company appears to be managing the transition smoothly.

Positives

• The separation of Andy Sassine was mutually agreed upon and amicable, with no reported disagreements on company operations or policies, which minimizes potential internal conflict.
• The company has a clear succession plan for the interim CFO/PAO role, appointing an internal candidate, Joe Roberts, who has been with the company since 2018 and has relevant financial experience.
• The Board acted promptly to adjust its size following the director's departure, maintaining efficient corporate governance.

Negatives

• The departure of a Chief Financial Officer, especially one who was also a Board member, can introduce uncertainty regarding financial leadership and strategic direction.
• A significant severance package for Mr. Sassine, including a lump sum of $572,000, 18 months of COBRA premiums, and accelerated vesting of 134,689 unvested stock options, represents a notable expense for the company.
• The appointment of an 'interim' principal financial and accounting officer suggests that a permanent replacement search is ongoing, which could lead to a period of extended transition and potential disruption.

Risks

• Potential for disruption in financial operations and reporting during the transition period with an interim principal financial officer.
• Uncertainty regarding the long-term financial strategy until a permanent Chief Financial Officer is appointed.
• The need to find a suitable permanent replacement for a key executive role (CFO) and Board member, which can be a challenging and time-consuming process.

Future Outlook

The filing primarily details executive changes and severance terms, not providing explicit forward-looking statements or guidance on company performance or strategy. The appointment of an interim officer suggests a future search for a permanent CFO.

Management Comments

• Mr. Sassine indicated to the Company that his separation was not a result of any disagreement with the Company, the Board or the Company’s management on any matter relating to the Company’s operations, policies, or practices.
• The Company wishes you the best in your future endeavors.

Industry Context

This filing is specific to internal corporate governance and executive management changes. It does not provide information that directly relates to broader industry trends or competitive landscape. The biotechnology industry frequently sees executive movements, but this particular announcement does not offer specific insights into market dynamics or competitive positioning.

Comparison to Industry Standards

• The severance package for a departing CFO, including 12 months of base salary, accelerated equity vesting, and COBRA payments, is generally consistent with industry standards for executive separations in the biotechnology sector, particularly when the departure is amicable and not for cause.
• The appointment of an internal candidate, the Controller, as interim Principal Financial Officer and Principal Accounting Officer is a common practice to ensure continuity during a search for a permanent replacement, aligning with corporate governance best practices.

Management Changes

Corporate Governance

Legal Proceedings

• The Separation Agreement includes a comprehensive release of claims by Andy Sassine against the Company, covering various types of legal claims up to the date of signing.
• The agreement outlines conditions for cooperation in future investigations or legal proceedings involving the Company, with compensation for Mr. Sassine's assistance at a rate of $500 per hour (or $2,500 for work exceeding five hours in a single day).
• The agreement explicitly states that it does not prevent Mr. Sassine from filing complaints with government agencies (e.g., EEOC, SEC) or participating in investigations, though he waives rights to monetary benefits in such cases.

Related Party Transactions

• No related party transactions were disclosed in the filing other than the severance and equity arrangements for the departing CFO, which are standard in such executive separations.

Stakeholder Impact

• Shareholders: May experience short-term uncertainty due to executive transition, but the amicable nature and interim appointment aim to minimize disruption. The severance package represents a cost.
• Employees: The departure of a senior executive can impact morale or create uncertainty, but the internal promotion to an interim role might offer some stability.
• Customers/Suppliers: Unlikely to be directly impacted by this internal management change.

Next Steps

• Arcturus Therapeutics will conduct a search for a permanent Chief Financial Officer.
• Andy Sassine will complete his employment with the Company on December 31, 2025.
• Andy Sassine has a 7-day revocation period for the Separation Agreement, after which severance benefits and stock option modifications will be paid/implemented.
• Andy Sassine has until December 31, 2027, to exercise his stock options.

Key Dates

Recommendation

The departure of a Chief Financial Officer, even if amicable, introduces a degree of uncertainty regarding financial leadership and strategy. While an interim replacement has been named, the search for a permanent CFO will be a key factor for investors. The severance package, while standard, represents a cost. Given the lack of specific financial performance updates or strategic shifts in this filing, a 'hold' recommendation is appropriate as investors await further clarity on the permanent CFO appointment and any subsequent strategic direction.

Keywords

Arcturus Therapeutics, CFO Departure, Executive Change, Interim CFO, Corporate Governance, SEC Filing, ARCT, Biotechnology, Pharmaceuticals, Financial Officer